An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition...
- Mechanism
- Curator reviewed
IGF-1R stimulates proliferation, enables onogenic transformation, and suppresses apoptosis. Inhibitors of IGF-1R are expected to have broad utility in oncology since the over-expression of IGF-1R and/or its ligands or the down-regulation of ligand binding proteins occurs in numerous human malignancies including lung, colon, breast, prostate, brain and skin cancers. In addition, signaling through the IGF system has been implicated in protecting tumor cells from apoptosis induced by anti-cancer treatments such as cytotoxic agents and EGFR inhibitors.
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.Curator reviewed
- Formula / weight
- C26H23N5O · 421.504 g/mol (avg)
- Code names
- ASP-7487 · OSI-906 · OSI-906AA
Resolves to
PKCDDUHJAFVJJB-VLZXCDOPSA-NSMILESC[C@@]1(O)C[C@@H](C1)C1=NC(=C2N1C=CN=C2N)C1=CC=C2C=CC(=NC2=C1)C1=CC=CC=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Linsitinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account